BCI
IRLA

Brinker Capital Investments’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Brinker Capital Investments’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-51
Closed -$7.6K – 1834
2024
Q2 		$7.6K Hold
51
– – ﹤0.01% 1710
2024
Q1 		$10.7K Hold
51
– – ﹤0.01% 1681
2023
Q4 		$11.4K Hold
51
– – ﹤0.01% 1646
2023
Q3 		$11.4K Hold
51
– – ﹤0.01% 1607
2023
Q2 		$15.3K Hold
51
– – ﹤0.01% 1617
2023
Q1 		$15.8K Sell
51
-3
-6% -$587 ﹤0.01% 1551
2022
Q4 		$6.84K Buy
+54
New +$9.03K ﹤0.01% 1346

Other funds holding IRLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Brinker Capital Investments's IRLA Position: Q3 2024 in Review

Brinker Capital Investments sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2024, closing a stake of 51 shares — an estimated $7.6K sold.

Brinker Capital Investments first reported a position in IRLA in Q4 2022 and held it in 7 quarters. The position peaked at $15.8K in Q1 2023. 32 funds tracked by Wall St. Rank hold IRLA as of Q3 2024.

  • Brinker Capital Investments reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Brinker Capital Investments sold 51 IRulya Therapeutics Inc. Common Stock shares in Q3 2024, an estimated $7.6K.
  • Brinker Capital Investments first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2022 and held it in 7 quarters.
  • Brinker Capital Investments's IRulya Therapeutics Inc. Common Stock position peaked at $15.8K in Q1 2023.
  • 32 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2024.

Based on Brinker Capital Investments's 13F filing for Q3 2024, filed 31 Jul 2025.